Neoadjuvant Chemotherapy Clinical Trials

13 recruiting

Neoadjuvant Chemotherapy Trials at a Glance

14 actively recruiting trials for neoadjuvant chemotherapy are listed on ClinicalTrialsFinder across 6 cities in 6 countries. The largest study group is Phase 3 with 5 trials, with the heaviest enrollment activity in Guangzhou, Hangzhou, and Gothenburg. Lead sponsors running neoadjuvant chemotherapy studies include Second Affiliated Hospital, School of Medicine, Zhejiang University, Fujian Medical University Union Hospital, and European Institute of Oncology.

Browse neoadjuvant chemotherapy trials by phase

Treatments under study

About Neoadjuvant Chemotherapy Clinical Trials

Looking for clinical trials for Neoadjuvant Chemotherapy? There are currently 13 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Neoadjuvant Chemotherapy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Neoadjuvant Chemotherapy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 114 of 14 trials

Recruiting
Early Phase 1

Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer

Breast CancerHER2-positive Breast CancerLocally Advanced Breast Cancer+1 more
Alison Stopeck30 enrolled1 locationNCT06220214
Recruiting
Not Applicable

Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in IBC

Sentinel Lymph Node Biopsy (SLNB)Invasive Breast CarcinomaNeoadjuvant Chemotherapy
European Institute of Oncology75 enrolled1 locationNCT07080944
Recruiting
Phase 3

Megestrol Acetate in Improving Neoadjuvant Chemotherapy-Related Weight Loss in Locally Advanced CRC

Weight LossNeoadjuvant Chemotherapy
Sixth Affiliated Hospital, Sun Yat-sen University60 enrolled1 locationNCT06998758
Recruiting

The Better, Harder, Faster, Stronger Study

Ovarian CancerEndometrial CancerNeoadjuvant Chemotherapy+2 more
Wake Forest University Health Sciences35 enrolled1 locationNCT07220512
Recruiting

Bladder Cancer Staging and Prediction of New Adjuvant Chemotherapy Efficacy Based on Deep Learning and Transfer Learning in Ultrasound-Magnetic Resonance-Pathology Multimodal Multiscale

Bladder CancerNeoadjuvant ChemotherapyDeep Learning+2 more
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University480 enrolled1 locationNCT07051083
Recruiting

Comparative Study Between Immediate Surgery Versus Neoadjuvant Chemotherapy for Management of Resectable Pancreatic Cancer

SurgeryNeoadjuvant ChemotherapyResectable Pancreatic Cancer+1 more
Minia University30 enrolled1 locationNCT06978322
Recruiting
Not Applicable

Photoacoustic/Ultrasound Imaging for Breast Nodule Diagnosis, Molecular Classification, and Neoadjuvant Chemotherapy Response Evaluation

Breast CancerBreast MassesBreast Cancer Treated with Neoadjuvant Chemotherapy
Peking Union Medical College Hospital500 enrolled1 locationNCT06908291
Recruiting
Phase 4

Effect of Neoadjuvant Chemotherapy on Cardiac Function of Perioperative Patients With Breast Cancer and New Strategies for Anesthesia

Breast CancerNeoadjuvant ChemotherapyPerioperative Period+2 more
Fujian Medical University Union Hospital496 enrolled1 locationNCT06497660
Recruiting

Organoids Based Drug Sensitivity in Neoadjuvant Chemotherapy of Breast Cancer

Breast CancerNeoadjuvant ChemotherapyOrganoids
Second Affiliated Hospital, School of Medicine, Zhejiang University58 enrolled1 locationNCT06155305
Recruiting
Phase 3

Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC

SurgeryPancreas CancerNeoadjuvant Chemotherapy+3 more
Sahlgrenska University Hospital432 enrolled1 locationNCT06714604
Recruiting
Phase 3

NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer)

Neoadjuvant ChemotherapyResectable Pancreatic CancerEffects of Chemotherapy
Seoul National University Hospital609 enrolled2 locationsNCT05529940
Recruiting
Phase 2

Neoadjuvant Chemotherapy Combined With PD-1 + Radical Radiotherapy in Locally Advanced Cervical Cancer

Cervical CancerRadiotherapyNeoadjuvant Chemotherapy+1 more
Shanghai Jiao Tong University Affiliated Sixth People's Hospital36 enrolled1 locationNCT05554276
Recruiting
Phase 3

Neoadjuvant Chemotherapy Followed by Chemoradiation Versus Chemoradiation for Stage IIIC Cervical Cancer Patients: A Randomized Phase III Trial

Cervical CancerNeoadjuvant ChemotherapyBulky Neoplasm
Sun Yat-sen University280 enrolled1 locationNCT05367206
Recruiting
Phase 2Phase 3

Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer

HER2-negative Breast CancerNeoadjuvant Chemotherapy
Second Affiliated Hospital, School of Medicine, Zhejiang University260 enrolled1 locationNCT04576143